Get the Stockscreener App
1.05
0.96%
0.01
After Hours:
1.01
-0.04
-3.81%
Phio Pharmaceuticals Corp stock is traded at $1.05, with a volume of 85,754.
It is up +0.96% in the last 24 hours and up +8.25% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
See More
Previous Close:
$1.04
Open:
$1.055
24h Volume:
85,754
Relative Volume:
0.15
Market Cap:
$12.20M
Revenue:
-
Net Income/Loss:
$-10.93M
P/E Ratio:
-0.7303
EPS:
-1.4378
Net Cash Flow:
$-10.72M
1W Performance:
-2.78%
1M Performance:
+8.25%
6M Performance:
+1.94%
1Y Performance:
-61.68%
1-Day Range:
$1.03
$1.0699
1-Week Range:
$1.03
$1.14
52-Week Range:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.05 | 12.08M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
PHIO|Phio Pharmaceuticals Corp|Price:1.040|Chg%:-0.030 - TradingKey
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TradingKey - TradingKey
Phio Pharmaceuticals Corp (PHIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Phio Pharmaceuticals Market Sentiment - Benzinga España
Phio Pharmaceuticals Corp. Revenue Breakdown – NASDAQ:PHIO - TradingView
PHIO|Phio Pharmaceuticals Corp|Price:1.010| - TradingKey
PHIO|Phio Pharmaceuticals Corp|Price:1.055|Chg%:+0.015 - TradingKey
Phio Pharmaceuticals Corp (PHIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Phio Pharmaceuticals (PHIO) Edges Higher, Testing Key Resistance at $1.13Sector ETF Flow - dars.gov.et
Phio Pharma corrects date for Renmark virtual non-deal roadshow presentation - Bitget
Phio Pharmaceuticals to present its INTASYL siR... - Pluang
Phio Pharmaceuticals CEO Robert Bitterman to Showcase INTASYL Gene Silencing Platform at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals to Showcase INTASYL siRNA Platform and PH-762 Skin Cancer Therapy at Renmark Virtual Roadshow on July 28, 2026 - Kalkine Media
Phio Pharmaceuticals Appoints Dr. R. Todd Plott to Board of Directors, Strengthening Expertise in Dermatologic Research and Commercialization – Minichart - Minichart
Phio Pharmaceuticals appoints dermatologist to board By Investing.com - Investing.com South Africa
Phio Pharmaceuticals appoints dermatologist to board - Investing.com
Phio Pharmaceuticals adds dermatology expert to board - TipRanks
Phio Pharmaceuticals adds R. Todd Plott to its Board, joins Governance Committee - TradingView
Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors - The Globe and Mail
Phio Pharmaceuticals Strengthens Board with Dermatology Expert Dr. R. Todd Plott Amid PH-762 Clinical Progress - Kalkine Media
Phio Pharmaceuticals (PHIO) Rises 3% to $1.03, Tests Key Resistance at $1.08TPO Profile - dars.gov.et
Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision - EIN Presswire
Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones - Yahoo Finance
Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan - Investing.com Canada
Phio's INTASYL patent portfolio consists of 54 issued patents - Stock Titan
Phio Pharmaceuticals Expands Global Patent Portfolio with Multiple Approvals in U.S., Canada, and Japan for INTASYL siRNA Technology - Kalkine Media
Enterprise value to EBITDA forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to book forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Slips 1.92% as Stock Tests Key Support at $0.97Sign of Strength - dars.gov.et
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
PHIO Q1 2026 Earnings: EPS Misses Estimates as Biotech Continues Clinical DevelopmentAnalyst Earnings Estimate - dars.gov.et
Phio Pharmaceuticals Corp. (PHIO) Q1 2026 Earnings: Wider-than-Expected Loss Reflects R&D InvestmentEPS Estimate Trend - dars.gov.et
PHIO PE Ratio & Valuation, Is PHIO Overvalued - Intellectia AI
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - TMX Newsfile
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock - Investing.com
Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com - Investing.com Nigeria
[Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity - Stock Titan
Form 4 Phio Pharmaceuticals Corp For: 29 June By Investing.com - Investing.com South Africa
PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact - TradingView
PHIO: PH-762 achieved 85% response with no serious adverse events; next trial planned for early next year - TradingView
Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026 - TMX Newsfile
PHIO PHARMACEUTICALS CORP (PHIO) Stock Chart - ChartMill
Phio Pharmaceuticals (PHIO) Second Annual Centri Capital Conference Summary - Quartr
Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary - Quartr
Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762 - The National Law Review
PHIO Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Corp. Actuals & Estimates (MUN:44R1) - TradingView
44R1 Forecast — Price Target — Prediction for 2027 - TradingView
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):